Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

entecavir Oral Tablet [Baraclude]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
  • Prescrire international
  • 2017
 
Is this relevant?
2017
2017
Background and objective Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor… Expand
Is this relevant?
2014
2014
INTRODUCTION: [4-5] BARACLUDE® is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against… Expand
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • table 1
Is this relevant?
2013
2013
Entecavir (Baraclude®, Bristol-Myers Squibb) is a potent and selective antiviral agent that has demonstrated efficacy in patients… Expand
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Stable isotope-labeled [(13) C4 ]entecavir (1) was prepared in 11 steps. Commercially available [(13) C]guanidine hydrochloride… Expand
Is this relevant?
Review
2011
Review
2011
The oral deoxyguanosine nucleoside analogue entecavir (Baraclude®) has potent activity against hepatitis B virus (HBV) and a high… Expand
  • table I
  • table II
  • figure 1
  • table IV
  • table V
Is this relevant?
2010
2009
2009
Entecavir – An antiviral for chronic HBV infection Approved indication Entecavir (Baraclude™) is indicated for the treatment… Expand
Is this relevant?
Review
2006
Review
2006
Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?